The new antipsychotics and their therapeutic potential

Psychiatric Annals

Volumn 27, Issue 5, 1997, Pages 320-331

  Keck, Paul E ^a   McElroy, Susan L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031475354     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19970501-04     Document Type: Article

References (81)

1. Baldessarini RJ. Chemotherapy in Psychiatry. Cambridge, Mass: Harvard University Press; 1984:14-92.
2. Wirshing WC, Marder SR, Van Putten T, et al. Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1259-1266.
3. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry. 1964; 10:246-261.
4. Kane JM. Treatment of schizophrenia. Schizophr Bull. 1987; 13:133-156.
5. Carpenter WT. The deficit syndrome. Am J Psychiatry. 1994; 151:327-329.
6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192:481-483.
7. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976; 261:717-719.
8. Keck P Jr, Cohen BM, Baldessarini RJ, McElroy SL. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry. 1989; 146:1289-1292.
9. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press; 1992:241-251.
10. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789-796.
11. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press Ltd; 1992:1-13.
12. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 1996; 124:2-34.
13. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet. 1995; 345:557-562.
14. Gerlach J, Casey DE. New antipsychotics: preclinical and clinical research. Psychopharmacology: 1996; 124:1. Editorial.
15. Fitton A, Heel RC. Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs. 1990; 40:722-747.
16. Coward DM. General pharmacology of clozapine. Br J Psychiatry. 1992; 160(suppl 17):5-11.
17. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991; 350:610-614.
18. Richelson E, Elson A. Antagonism of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol. 1984; 103:197-214.
19. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 1980; 137:1518-1522.
20. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 1992; 7:261-284.
21. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmcology. 1996; 457:35-39.
22. Aprison MH, Takahasi R, Tachiki K. Hypersensitive serotonergic receptors involved in clinical depression - a theory. In: Haber B, Aprison MH, eds. Neuropharmacology and Behavior. New York, NY: Plenum; 1978:23-48.
23. Keck PE Jr, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology. 1994; 114:529-538.
24. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds of the five cloned human muscarnic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 1983; 260:576-580.
25. Litman RE, Hong WW, Weissman EM, et al. Idazoxan, an alpha-2 antagonist augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol. 1993; 13:264-267.
26. Cohen BM, Lipinski JF. In vivo potencies of antipsychotic drugs un blocking alpha1, noradrenergic and dopamine D2 receptors: implications for drug mechanism of action. Life Sci. 1986; 39:2571-2580.
27. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992; 41:494-508.
28. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-835.
29. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology. 1989; 99:445-449.
30. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J Clin Psychiatry. 1995; 56:466-470.
31. Keck PE Jr, McElroy SL. Olanzapine: a novel antipsychotic medication. Today's Therapeutic Trends. 1996; 14:63-78.
32. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs. 1993; 2:281-293.
33. Seeman P, Van Tol HM. Dopamine receptor pharmacology. Curr Opin Neurol. 1993; 6:602-608.
34. Bymaster FP, Calligaro DO, Falcone JF, et al. Radio receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14:87-96.
35. Montgomery S, Beasley CM Jr, Tye NC. Olanzapine: an open-label study in schizophrenia. Presented at the Second International Conference on Schizophrenia; Vancouver, BC; 1992.
36. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olazapine trial. Neuropsychopharmacology. 1996; 14:111-124.
37. Beasley CM, Sanger T, Satterlee WG, et al. Olanzapine versus placebo: results of a double-blind fixed-dose trial. Psychopharmacology. 1996; 124:159-167.
38. Tran PV, Beasley CM, Tollefson GD, et al. Clinical efficacy and safety of increasing doses of olanzapine: a new atypical antipsychotic agent. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
39. Tollefson G, Beasley C, Tran P, et al. Olanzapine versus haloperidol: acute results of the multi-center trial. Presented at the 36th Annual Meeting of the New Clinical Drug Evaluation Unit; Boca Raton, Fla; 1996.
40. Tollefson GD, Sanger TM. Olanzapine versus haloperidol in the treatment of first episode psychosis. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1996.
41. Tran PV, Tollefson G, Hamilton S, Kintz A. Olanzapine vs. risperidone in the treatment of psychosis. Preliminary report. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1996.
42. Gaertner HG, Fisher E, Hoss J. Side effects of clozapine. Psychopharmacology. 1989; 99:S97-S100.
43. Leppig M, Bosch B, Naber D, et al. Clozapine in the treatment of 121 outpatients. Psychopharmacology. 1989; 99:S77-S79.
44. Lu Y, Sanger T, Beasley C, et al. Olanzapine in the treatment of schizoaffective disorder. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
45. Csernansky JG, Newcomer JG. Maintenance drug treatment for schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1267-1276.
46. Tran PV, Beasley CM Jr, Tollefson GD, et al. Acute and long-term results of the North American double-blind olanzapine trial. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
47. Satterlee W, Dellva MA, Beaskey C, et al. Effectiveness of olanzapine in long-term continuation treatment. Presented at the 149th Annual Meeting of the American Psychiatric Association; New York, NY; 1996.
48. Street JS, Tamura RN, Sanger TM, Tollefson GD. A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 34th Annual Meeting of the American College of Psychopharmacology; San Juan, Puerto Rico; 1995.
49. Wolters EC, Bermans PCM, Jansen ENH, et al. Olanzapine in the treatment of dopaminomimetic psychosis. Presented at the Eighth Annual Meeting of the European College of Neuropsychopharmacology; Venice, Italy; 1995.
50. Bennett JP Jr, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease, II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology. 1993; 43:1551-1555.
51. Sánchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development and Research. 1991; 22:239-250.
52. Hyttel J, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect. 1992; 89:61-69.
53. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 1996; 124:168-175.
54. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
55. Zborowski J, Schmitz P, Staser J, et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
56. Martin PT, Grebb JA, Schmitz P, et al. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Schizophr Res. 1994; 11:107. Abstract.
57. McEvoy JP, Borison R, Small J, et al. The efficacy and tolerability of sertinole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study. Schizophr Res. 1993; 9:244. Abstract.
58. Hale A, van der Burght M, Wehnert A, Sloth-Nielsen M. A European dose-ranging study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenia patients. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1996.
59. Hirschfeld RMA. Schizoaffective disorder and psychotic mania. Psychiatric Annals. 1996; 26:S435-S439.
60. Schulz C, Staser J, Schmitz P, et al. An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenic patients. Eur Neuropsychopharmacol. 1995; 5:348A. Abstract.
61. Zborowski J, Schmitz P, Sebree T, et al. An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenia and other psychotic disorders. Eur Neuropsychopharmacol. 1995; 5:348A. Abstract.
62. Daniel DG, Schmitz PJ, Holgate KL, et al. Two open-label, long-term safety studies of sertindole. Eur Neuropsychopharmacol. 1995; 5:348A. Abstract.
63. Goldstein JM, Arvanitis LA. ICI 204,636 (SeroquelTM): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Review. 1995; 1:50-73.
64. Fabre LF. A multicenter, open, pilot trial of ICI 204,636 in hospitalized patients with acute psychotic symptomatology. Schizophr Res. 1993; 9:237A. Abstract.
65. Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995; 17:366-378.
66. Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 1996; 16:158-169.
67. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, the Seroquel Study Group. The efficacy and safety of ICI 204,636 (Seroquel) in patients with schizophrenia: a high- and low-dose, double-blind comparison with placebo. Arch Gen Psychiatry. In press.
68. Arvanitis LA, Miller BG. 'Seroquel' (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. Presented at the 20th Biannual Meeting of the Collegium Internationale Neuro-Psychopharmacologium; Melbourne, Australia; 1996.
69. Fleischhacker WW, Link CG. A multicenter, double-blind, randomized comparison of dose and dose regimen of 'Seroquel' in the treatment of patients with schizophrenia. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; 1995.
70. Link C, Smith A, Miller B, Seroquel Study Group. A multicenter, double-blind, controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalized patients with acute exacerbation of subchronic and chronic schizophrenia. Eur Neuropsychopharmacol. 1994; 4(3, special issue):385. Abstract.
71. Casey DE. 'Seroquel' (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Expert Opinion in Investigational Drugs. 1996; 5:939-957.
72. Hamner MB, Arvanitis LA, Miller BE, Link CGG, Hong W. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull. 1996; 32:107-110.
73. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schultz DW, Lebel LA. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995; 275:101-113.
74. Ko G, Goff D, Hertz L, et al. Status report: ziprasidone. Schizophr Res. 1995; 15:154. Abstract.
75. Harrigan E, Morrissey M, Buffenstein A, et al. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder. European Psychiatry. 1996; 11(suppl 4):112S. Abstract.
76. Reeves KR, Harrigan EP. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder. European Psychiatry. 1996; 11(suppl 4):422S. Abstract.
77. Van Putten T, Mutalipassi L, Malkin M. Phenothiazine-induced decompensation. Arch Gen Psychiatry. 1974; 30:102-105.
78. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry. 1974; 31:67-72.
79. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991; 52:411-414.
80. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry. 1995; 56:411-417.
81. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry. 1996; 153:759-764.